<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915586</url>
  </required_header>
  <id_info>
    <org_study_id>FF-2020-008</org_study_id>
    <secondary_id>NMRR-19-2940-51404</secondary_id>
    <nct_id>NCT04915586</nct_id>
  </id_info>
  <brief_title>Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management</brief_title>
  <official_title>Short Duration High Intensity Intrapleural Alteplase With Pulmozyme (DNase) in Pleural Infection Management- Single Centre Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to assess the efficacy of the modified regimen short duration&#xD;
      intrapleural 16mg alteplase (Actilyse, Boehringer Ingelheim) with 5mg DNase (Pulmozyme&#xD;
      Hoffmann-La Roche Ltd) in patients with pleural infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The regimen 10 mg alteplase and 5 mg DNase twice daily that was used in MIST-2 trial is still&#xD;
      an empiric choice. The rationale of using 3 doses of 16 mg alteplase dose (with supplementary&#xD;
      5 mg DNase) in our study was governed by the formulation of alteplase in our country (50 mg&#xD;
      per ampoule); hence, it is best used within 24 hours following reconstitution as its&#xD;
      biochemical stability up to 24 hours as assessed by in vitro clot lysis assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The radiologists were blinded to patient identity and intervention timing</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic improvement in pleural opacity on chest radiograph</measure>
    <time_frame>Day 7</time_frame>
    <description>measured in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pleural fluid volume drained</measure>
    <time_frame>Day 7</time_frame>
    <description>measured in mls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in inflammatory markers C-Reactive Protein (CRP )</measure>
    <time_frame>Day 7</time_frame>
    <description>reduction of inflammatory markers trend</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White cell count</measure>
    <time_frame>Day 7</time_frame>
    <description>changes in inflammatory markers trend</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalisation</measure>
    <time_frame>upto 30 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the need of surgical referral</measure>
    <time_frame>upto 30 days</time_frame>
    <description>if evidence of clinical deterioration post intrapleural therapy such as intrapleural haemorrhage or hypotension or less than 50% resolution of effusion on chest-xray post intrapleural therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events post therapy</measure>
    <time_frame>Day 7</time_frame>
    <description>pain, bleeding events, hemodynamic stability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate at day 30 post intervention</measure>
    <time_frame>30 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Loculated Empyema</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours&#xD;
Intervention Drug: Combination Alteplase and pulmozyme (DNase)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg</intervention_name>
    <description>Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Combination Tissue Plasminogen Activator (t-PA) and Pulmozyme (DNase)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patient with age more than 17 year old&#xD;
&#xD;
          -  evidence of complex parapneumonic effusion or empyema; with poor pleural fluid&#xD;
             drainage of â‰¤150 mL after 24 hours of insertion of chest drain&#xD;
&#xD;
          -  clinical evidence of infection such as fever and or elevated C-reactive protein (CRP)&#xD;
             or white-cell count&#xD;
&#xD;
          -  complex pleural effusion proven by ultrasound&#xD;
&#xD;
          -  pleural fluid analysis that fulfilled at least one of the characteristics: frank pus,&#xD;
             exudative nature (according to light's criteria), gram stain or culture positive,&#xD;
             lactate dehydrogenase (LDH) &gt; 1000 U/L, pH &lt; 7.2 and/or glucose level &lt; 3.3mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy to pulmozyme or alteplase&#xD;
&#xD;
          -  acute stroke, active bleeding diathesis&#xD;
&#xD;
          -  major surgery in past 5 days&#xD;
&#xD;
          -  previous pneumonectomy on the infected side&#xD;
&#xD;
          -  bronchopleural fistula&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  coagulopathy (INR &gt; 2, APTT &gt;100, platelet count &lt; 50,000 cells)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Faisal Abdul Hamid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Kebangsaan Malaysia Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Mohamed Faisal Abdul Hamid</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Intrapleural fibrinolysis, pleural infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Empyema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

